ANDA 205187, held by Micro Labs Ltd India. Amoxicillin; Clavulanate Potassium.
As of Nov 22, 2026, ANDA 205187 (Amoxicillin and Clavulanate Potassium), held by Micro Labs Ltd India, was first approved by FDA on May 21, 2021, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 21, 2021 | Original application | Approved | None posted |
| Amoxicillin and Clavulanate Potassium200MG/5ML;EQ 28.5MG BASE/5ML · for suspension;oral | Amoxicillin; Clavulanate Potassium | Discontinued |
| Amoxicillin and Clavulanate Potassium400MG/5ML;EQ 57MG BASE/5ML · for suspension;oral | Amoxicillin; Clavulanate Potassium | Discontinued |
| May 1, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 16, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 21, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters